刘圣兰，博士，硕士生导师，准聘教授。毕业于中山大学，比利时鲁汶大学访问学者。主要研究方向：肿瘤分子靶向治疗与肿瘤药理学研究。主持国家自然科学基金课题2项、江西省科技厅自然科学基金项目2项。获2024年江西省自然科学奖二等奖1项（排名第三）。申请发明专利4项，授权2项。参编高等教育出版社教材2部。以第一作者/通讯作者身份在Mol Cancer等期刊发表论文十余篇。代表性论文及中科院分区：

1.Wei Dai, Dong Xie, Hao Huang,et al.,Shenglan Liu*. New insights into the dule roles CDK12 in human cancers: mechanisms and interventions for cancer therapy.J Pharm Anal,2025, 15(7):101173.（中科院一区Top）

2.Shenglan Liu^#, Wei Dai,et al., Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets.Mol Cancer, 2024, 23(1): 122.（中科院一区Top）

3.Wei Dai, Junhong Wu, Xiaopeng Peng, Wen Hou, Hao Huang, Qilai Cheng, Zhiping Liu, Walter Luyten, Liliane Schoofs, Jingfeng Zhou*,Shenglan Liu*. CDK12 orchestrates super-enhancer-associated CCDC137 transcription to direct hepatic metastasis in colorectal cancer.Clin Transl Med, 2022;12:e1087.（中科院一区）

4.JingfengZhou^#,Shenglan Liu^#, Yun Wang, et al.,Salinomycin effectively eliminates cancer stem-like cells and obviates hepatic metastasis in uveal melanoma[J].Mol Cancer, 2019, 18(1): 159.（中科院一区Top)

5.Shenglan Liu, Liangmei He, Junhong Wu, Xinqiang Wu, Lu Xie, Wei Dai, Lingxia Chen, Fuhua Xie, Zhiping Liu. DHX9 contributes to the malignant phenotypes of colorectal cancer via activating NF‑κB signaling pathway.Cell Mol Life Sci, 2021, 78(24): 8261-8281.（中科院二区Top）

6.Shenglan Liu,Junhong Wu, Hao Huang,et al.,Effects of solamargine in hepatic metastasis of colorectal cancer: induction of ferroptosis and elimination of cancer stem cells.Chin Med, 2025, 20(1):110.（中科院二区）

7.Wei Dai, CaiyaoGuo, Yu Wang, Yumei Li, Renjian Xie, Junhong Wu, Baole Yao, Dong Xie, Ling He, Yingying Li, Hao Huang, Yun Wang*,Shenglan Liu*. Identification of hub genes and pathways in lung metastatic colorectal cancer.BMC Cancer,2023; 23: 323.（中科院二区）.